Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
Details : Renazorb (Lanthanum Dioxycarbonate) is an investigational next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology. it is being developed for the treatment of hyperphosphatemia in patients with chronic kidney ...
Product Name : Renazorb
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2022
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Unicycive Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the terms of the asset purchase agreement, Unicycive has acquired global rights for Renazorb and all its trademark and associated patents, and Spectrum has received an equity interest in Unicycive along with milestone and royalty payments.
Product Name : Renazorb
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 14, 2020
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Unicycive Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2017
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2014
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2012
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 26, 2012
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2012
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2011
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Lanthanum Carbonate in Calciphylaxis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2011
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
Details : Undisclosed
Product Name : Fosrenol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2010
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
